New Therapies

Driven by Big Data and Artificial Intelligence

Pharnext is an advanced clinical-stage biopharmaceutical company

Icon

Disease Molecular Networks

Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.

Icon

Innovative Drug Combinations

Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.

Icon

Optimal Doses

Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.

A visionary concept in drug development
PLEOTHERAPY™
Our innovative drug discovery model leverages artificial intelligence (AI) to analyze genomic big data, build disease molecular networks and identify generic compounds and/or New Chemical Entities (NCEs) that are then combined to create new effective therapies across various therapeutic areas.

Two first-in-class products in clinical development
01
PXT3003
Charcot-Marie-Tooth Disease type 1A (CMT1A)
PXT3003 is a novel synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice daily.

ExploreExplore
02
PXT864
Alzheimer’s Disease
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice daily.

Next step
About